Clinical Trials Directory

Comparison of Transdermal and Oral Estrogens in Adolescents With Ovarian Failure

To directly compare the safety (by laboratory evaluation) and efficacy (feminization and growth) of three commonly used estrogen preparations in adolescent patients with ovarian failure, either due to congenital causes (Turner syndrome) or medical therapies. We hypothesize that transdermal estrogen will have equivalent efficacy and a more favorable safety profile in comparison with conventional oral estrogen replacement.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : 17beta Estradiol
  • drug : Progesterone, micronized
  • drug : 17Beta Estradiol - transdermal
  • drug : Conjugated estrogens

Phase: N/A


Ages Eligible For Study:

12 Years - 18 Years

Inclusion Criteria

in whom initiation of estrogen therapy has been recommended due to ovarian failure - Outpatients - age >=12 years to 17.99 years old

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sejal Shah
Not Recruiting

Footer Links: